Guardian Pharmacy Services reported a significant increase in net income for the nine months ended September 30, 2026, reaching $54.8 million compared to $27.7 million in the prior year period. This growth was driven by improved gross margins and a substantial $11.2 million gain in other income, despite relatively flat year-over-year revenue of $1.06 billion.
Guardian Pharmacy Services reported Q3 2026 financial results with revenue of $371.1 million and net income of $19.1 million. The company raised its full-year 2026 guidance for both revenue and Adjusted EBITDA, citing strong organic growth in residents served and successful integration of recent acquisitions.
Term
Q3 2026
“We are very pleased with our third-quarter performance, highlighted by strong resident and prescription growth. Absent the price reductions from the IRA, revenues would have been up high single digits compared to the third quarter of 2025, mostly driven by organic growth.”
Fred Burke, President and Chief Executive Officer
“With favorable industry fundamentals, a substantial runway for growth, and a liquid balance sheet, we believe Guardian is well positioned to generate durable growth and attractive long-term returns for shareholders.”